Your browser doesn't support javascript.
loading
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.
Lewis, Nathaniel M; Zhu, Yuwei; Peltan, Ithan D; Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar; Steingrub, Jay S; Shapiro, Nathan I; Duggal, Abhijit; Bender, William S; Taghizadeh, Leyla; Brown, Samuel M; Hager, David N; Gong, Michelle N; Mohamed, Amira; Exline, Matthew C; Khan, Akram; Wilson, Jennifer G; Qadir, Nida; Chang, Steven Y; Ginde, Adit A; Mohr, Nicholas M; Mallow, Christopher; Lauring, Adam S; Johnson, Nicholas J; Gibbs, Kevin W; Kwon, Jennie H; Columbus, Cristie; Gottlieb, Robert L; Raver, Catherine; Vaughn, Ivana A; Ramesh, Mayur; Johnson, Cassandra; Lamerato, Lois; Safdar, Basmah; Casey, Jonathan D; Rice, Todd W; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Talbot, H Keipp; Baughman, Adrienne; Womack, Kelsey N; Swan, Sydney A; Harker, Elizabeth; Price, Ashley; DeCuir, Jennifer; Surie, Diya; Ellington, Sascha; Self, Wesley H.
Afiliación
  • Lewis NM; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Zhu Y; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Peltan ID; Department of Medicine, Intermountain Medical Center, Murray, Utah, and University of Utah, Salt Lake City, Utah, USA.
  • Gaglani M; Baylor Scott and White Health, Temple and Dallas, Texas, and Texas A&M University College of Medicine, Temple, Texas, USA.
  • McNeal T; Baylor Scott and White Health, and Baylor College of Medicine, Temple, Texas, USA.
  • Ghamande S; Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA.
  • Steingrub JS; Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA.
  • Shapiro NI; Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Duggal A; Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Bender WS; Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Taghizadeh L; Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
  • Brown SM; Department of Medicine, Intermountain Medical Center, Murray, Utah, and University of Utah, Salt Lake City, Utah, USA.
  • Hager DN; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Gong MN; Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Mohamed A; Department of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Exline MC; Department of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Khan A; Department of Medicine, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Wilson JG; Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Qadir N; Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
  • Chang SY; Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
  • Ginde AA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Mohr NM; Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Mallow C; Department of Medicine, University of Miami, Miami, Florida, USA.
  • Lauring AS; Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
  • Johnson NJ; Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA.
  • Gibbs KW; Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Kwon JH; Department of Medicine, Washington University, St.Louis, Missouri, USA.
  • Columbus C; Baylor, Scott and White Health, Dallas, Texas, USA.
  • Gottlieb RL; Baylor University Medical Center Dallas, Baylor, Scott & White Heart and Vascular Hospital, Baylor, Scott and White Research Institute, Dallas, Texas, USA.
  • Raver C; Baylor, Scott and White Health, Dallas, Texas, USA.
  • Vaughn IA; Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.
  • Ramesh M; Division of Infectious Diseases, Henry Ford Health, Detroit, Michigan, USA.
  • Johnson C; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Lamerato L; Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.
  • Safdar B; Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Casey JD; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Rice TW; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Halasa N; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Chappell JD; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Grijalva CG; Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Talbot HK; Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Baughman A; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Womack KN; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Swan SA; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Harker E; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Price A; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • DeCuir J; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Surie D; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Ellington S; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Self WH; Department of Emergency Medicine, Vanderbilt Institute for Clinical and Translational Research, and Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Clin Infect Dis ; 78(4): 1056-1064, 2024 Apr 10.
Article en En | MEDLINE | ID: mdl-38051664
ABSTRACT

BACKGROUND:

Influenza circulation during the 2022-2023 season in the United States largely returned to pre-coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match to the vaccine strain.

METHODS:

To understand effectiveness of the 2022-2023 influenza vaccine against influenza-associated hospitalization, organ failure, and death, a multicenter sentinel surveillance network in the United States prospectively enrolled adults hospitalized with acute respiratory illness between 1 October 2022, and 28 February 2023. Using the test-negative design, vaccine effectiveness (VE) estimates against influenza-associated hospitalization, organ failures, and death were measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative control-patients.

RESULTS:

A total of 3707 patients, including 714 influenza cases (33% vaccinated) and 2993 influenza- and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative controls (49% vaccinated) were analyzed. VE against influenza-associated hospitalization was 37% (95% confidence interval [CI] 27%-46%) and varied by age (18-64 years 47% [30%-60%]; ≥65 years 28% [10%-43%]), and virus (A[H3N2] 29% [6%-46%], A[H1N1] 47% [23%-64%]). VE against more severe influenza-associated outcomes included 41% (29%-50%) against influenza with hypoxemia treated with supplemental oxygen; 65% (56%-72%) against influenza with respiratory, cardiovascular, or renal failure treated with organ support; and 66% (40%-81%) against influenza with respiratory failure treated with invasive mechanical ventilation.

CONCLUSIONS:

During an early 2022-2023 influenza season with a well-matched influenza vaccine, vaccination was associated with reduced risk of influenza-associated hospitalization and organ failure.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus de la Influenza A / Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Adolescent / Adult / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus de la Influenza A / Vacunas contra la Influenza / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Adolescent / Adult / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos